These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21217789)

  • 1. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.
    Jantunen E; Fruehauf S
    Bone Marrow Transplant; 2011 May; 46(5):627-35. PubMed ID: 21217789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
    Duarte RF; Shaw BE; Marín P; Kottaridis P; Ortiz M; Morante C; Delgado J; Gayoso J; Goterriz R; Martínez-Chamorro C; Mateos-Mazón JJ; Ramírez C; de la Rubia J; Achtereekte H; Gandhi PJ; Douglas KW; Russell NH
    Bone Marrow Transplant; 2011 Jan; 46(1):52-8. PubMed ID: 20305700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.
    Varmavuo V; Mäntymaa P; Silvennoinen R; Nousiainen T; Kuittinen T; Jantunen E
    Transfusion; 2013 May; 53(5):1024-32. PubMed ID: 22897584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.
    Worel N; Fritsch G; Agis H; Böhm A; Engelich G; Leitner GC; Geissler K; Gleixner K; Kalhs P; Buxhofer-Ausch V; Keil F; Kopetzky G; Mayr V; Rabitsch W; Reisner R; Rosskopf K; Ruckser R; Zoghlami C; Zojer N; Greinix HT
    J Clin Apher; 2017 Aug; 32(4):224-234. PubMed ID: 27578390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
    Fruehauf S; Ehninger G; Hübel K; Topaly J; Goldschmidt H; Ho AD; Müller S; Moos M; Badel K; Calandra G
    Bone Marrow Transplant; 2010 Feb; 45(2):269-75. PubMed ID: 19597422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
    Bhamidipati PK; Fiala MA; Grossman BJ; DiPersio JF; Stockerl-Goldstein K; Gao F; Uy GL; Westervelt P; Schroeder MA; Cashen AF; Abboud CN; Vij R
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2065-2069. PubMed ID: 28797783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
    Costa LJ; Alexander ET; Hogan KR; Schaub C; Fouts TV; Stuart RK
    Bone Marrow Transplant; 2011 Jan; 46(1):64-9. PubMed ID: 20383210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis.
    Badar T; Dhakal B; Szabo A; Padmanabhan A; Johnson BD; Heidtke S; Esselmann J; Chhabra S; Hamadani M; Hari P; D'Souza A
    J Clin Apher; 2019 Dec; 34(6):686-691. PubMed ID: 31566813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.
    Jantunen E; Varmavuo V
    Expert Opin Biol Ther; 2014 Jun; 14(6):851-61. PubMed ID: 24673120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
    Hundemer M; Engelhardt M; Bruckner T; Kraeker S; Schmitt A; Sauer S; Neben K; Witzens-Harig M; Goldschmidt H; Ho AD; Wuchter P
    J Clin Apher; 2014 Dec; 29(6):299-304. PubMed ID: 24771277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood graft composition after plerixafor injection in patients with NHL.
    Varmavuo V; Mäntymaa P; Nousiainen T; Valonen P; Kuittinen T; Jantunen E
    Eur J Haematol; 2012 Aug; 89(2):128-35. PubMed ID: 22536949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous Stem Cell Mobilization in the Age of Plerixafor.
    Cooper DL; Medoff E; Patel N; Baker J; Pratt K; Foss F; Seropian SE; Perreault S; Wu Y
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):411-6. PubMed ID: 27245311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.
    Jantunen E; Varmavuo V; Valtola J
    Expert Rev Hematol; 2016 Aug; 9(8):723-32. PubMed ID: 27355397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.
    Yuan S; Palmer JM; Tsai NC; Dagis A; Nademanee A; Wang S
    Hematol Oncol; 2017 Sep; 35(3):281-287. PubMed ID: 26928577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.
    Calandra G; McCarty J; McGuirk J; Tricot G; Crocker SA; Badel K; Grove B; Dye A; Bridger G
    Bone Marrow Transplant; 2008 Feb; 41(4):331-8. PubMed ID: 17994119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
    Micallef IN; Stiff PJ; Nademanee AP; Maziarz RT; Horwitz ME; Stadtmauer EA; Kaufman JL; McCarty JM; Vargo R; Cheverton PD; Struijs M; Bolwell B; DiPersio JF
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1187-1195. PubMed ID: 29410180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.